Summary by Moomoo AI
Avalo Therapeutics, Inc. has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity and securities offering related to a business combination transaction. The offering, which began on March 27, 2024, has already seen $130,601,986 sold out of a total offering amount of $199,976,986. The securities are being offered in connection with a merger involving Project Athens Merger Sub, Inc., AlmataBio, Inc., and Second Project Athens Merger Sub, LLC. Avalo Therapeutics has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company, based in Rockville, Maryland, operates in the biotechnology industry and has listed several executive officers and directors in the filing. No sales commissions have been reported, but finder's fees of approximately $6,937,500 have been estimated. The proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters beyond their usual compensation.